Nano-Micro Letters

Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin to Drug-Resistant Cancer Cells

Daoxia Guo1, #, Xiaoyuan Ji1, #, Fei Peng1, Yiling Zhong1, Binbin Chu1, Yuanyuan Su1, *, Yao He1, *

Abstract | Support Info
icon-htmlFull Text Html
icon-pdf-smPDF w/ Links
icon-citExport Citation
+Show more

Nano-Micro Lett. (2019) 11: 27

First Online: 25 March 2019 (Article)


*Corresponding author. E-mail: (Yuanyuan Su); (Yao He)





The development of effective and safe vehicles to deliver small interfering RNA (siRNA) and chemotherapeutics remains a major challenge in RNA interference -based combination therapy with chemotherapeutics, which has emerged as a powerful platform to treat drug-resistant cancer cells. Herein, we describe the development of novel all-in-one fluorescent silicon nanoparticles (SiNPs)-based nanomedicine platform for imaging-guided co-delivery of siRNA and doxorubicin (DOX). This approach enhanced therapeutic efficacy in multidrug-resistant breast cancer cells (i.e., MCF-7/ADR cells). Typically, the SiNP-based nanocarriers enhanced the stability of siRNA in a biological environment (i.e., medium or RNase A) and imparted the responsive release behavior of siRNA, resulting in approximately 80% down-regulation of P-glycoprotein expression. Co-delivery of P-glycoprotein siRNA and DOX led to > 35-fold decrease in the half maximal inhibitory concentration of DOX in comparison to free DOX, indicating the pronounced therapeutic efficiency of the resultant nanocomposites for drug-resistance breast cancer cells. The intracellular time-dependent release behaviors of siRNA and DOX were revealed through tracking the strong and stable fluorescence of SiNPs. These data provide valuable information for designing effective RNA interference-based co-delivery carriers.



Fluorescent silicon nanoparticles; Drug resistance; Gene therapy; Bioimaging

 View: Full Text HTML | PDF w/ Links